-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8

Benzinga·07/23/2026 10:57:30
Listen to the news
Oppenheimer analyst Leland Gershell initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $8.